Download Mobile App

Video Library

Events

more events

13 May 2025 - 16 May 2025

ESGAR 2025 – Annual Meeting of the European Society of Gastrointestinal and Abdominal Radiology

14 May 2025 - 16 May 2025

25th MEDEXPO Africa 2025

14 May 2025 - 17 May 2025

ASCVTS 2025 – 33rd Annual Meeting of the Asian Society for Cardiovascular and Thoracic Surgery

Partner Sites

MedImaging

CT-Based Deep Learning-Driven Tool to Enhance Liver Cancer Diagnosis

AI Improves Early Detection of Interval Breast Cancers

New MRI Technique Reveals True Heart Age to Prevent Attacks and Strokes

AI Tool Predicts Relapse of Pediatric Brain Cancer from Brain MRI Scans

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Cardinal to Acquire Cordis Vascular Technology for USD 1.94 Billion

By HospiMedica International staff writers
Posted on 15 Mar 2015

US pharmaceutical and medical equipment maker Johnson & Johnson (J&J; New Brunswick, NJ, USA) has agreed to sell its Cordis vascular technology unit to Cardinal Health (Dublin, OH, USA) for USD 1.94 billion.

The acquisition follows a sequence of strategic moves for Cardinal Health in the areas of cardiology, wound management, and orthopedics, and is designed to elevate Cardinal Health to the status of a global manufacturer of cardiology and endovascular devices, as well as providing an opportunity to build a generic medical devices business that could be a powerful competitor to cardiovascular device companies such as Abbott Laboratories, Boston Scientific (Natick, MA, USA), and Medtronic.

The purchase of Cordis (Fremont, CA, USA) marks the continued departure of J&J from the cardiovascular stent business, a move that enables the company to focus on other areas that offer greater opportunities for growth. More...

J&J said, however, that it would continue to stay in the cardiovascular disease sector through its electrophysiology business, Biosense Webster, and its leading cardiovascular treatment Xarelto.

“With an aging population and the accompanying demand for less invasive medical treatments, health systems around the world are searching for the best way to bring quality care to their patients in the most cost-effective way,” said George Barrett, chairman and CEO of Cardinal Health. “The acquisition of Cordis reinforces our strategic position to address this need and strengthens an important growth driver in the Cardinal Health portfolio.”

“This initiative is part of our ongoing disciplined portfolio management approach to focus on our most promising opportunities to help patients and drive growth,” said Gary Pruden, worldwide chairman of the global surgery group at J&J. “Cordis has made significant contributions to the field of cardiovascular care, and we believe the business has a promising future with Cardinal Health, a company with which we have a long-standing relationship.”

Related Links:
Johnson & Johnson
Cardinal Health
Cordis

Visit expo >

Gold Member

STI Test

Vivalytic Sexually Transmitted Infection (STI) Array

Gold Member

12-Channel ECG

CM1200B

New

Needle Guide Disposable Kit

Verza

New

Intelligent Mattress System

DualPlus

Read the full article by registering today, it's FREE!

Free digital version edition of HospiMedica International sent by email on regular basis
Free print version of HospiMedica International magazine (available only outside USA and Canada).
Free and unlimited access to back issues of HospiMedica International in digital format
Free HospiMedica International Newsletter sent every week containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!